A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects
Status:
Completed
Trial end date:
2021-05-31
Target enrollment:
Participant gender:
Summary
Quizartinib, a selective FLT3 inhibitor, is being developed as a treatment for acute myeloid
leukemia (AML) and myelodysplastic syndrome (MDS). The absolute oral bioavailability of
quizartinib has not yet been studied. This study is designed to estimate quizartinib
bioavailability of quizartinib following oral and intravenous (IV) administration.